Joost de Bruijn
Fortune : 9 M $ au 31/05/2026
Fortune : 9 M $ au 31/05/2026
Joost D.
de Bruijn was the founder of Xpand Biotechnology BV, serving as President & Chief Executive Officer since 2005.
Dr. de Bruijn was the founder of Progentix Orthobiology BV, serving as Chief Executive Officer from 2007 to 2012.
Dr. de Bruijn is the founder of Kuros Biosciences Ltd., serving as Executive Director & President-Innovation since 2023.
Dr. de Bruijn is also the founder of Scinus Cell Expansion BV.
Dr. de Bruijn is currently a Professor at the University of London since 2014 and a Professor at Queen Mary University of London since 2004.
Former positions include Research Director at IsoTis SA and Professor at the University of Twente from 2011 to 2019.
Education includes a doctorate from the University of Leiden, conferred in 1993.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
KUROS BIOSCIENCES LTD. 0,83 % | 31/12/2025 | 325 276 ( 0,83 % ) | 9 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| KUROS BIOSCIENCES AG | Fondateur | - |
University of London
University of London Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 18/03/2014 |
Queen Mary University of London
Queen Mary University of London Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/2004 |
| Sociétés | Poste | Fin |
|---|---|---|
University of Twente
University of Twente Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/01/2019 |
Scinus Cell Expansion BV
Scinus Cell Expansion BV BiotechnologyHealth Technology Develops and manufactures bioreactor solutions that simplify & streamline the production of advanced cell therapies | Fondateur | - |
IsoTis SA
IsoTis SA BiotechnologyHealth Technology Develops biomedical products | Directeur Technique/Scientifique/R&D | - |
Xpand Biotechnology BV
Xpand Biotechnology BV BiotechnologyHealth Technology Develops innovative bioreactor technology for adherent cell expansion | Directeur Général | - |
Progentix Orthobiology BV
Progentix Orthobiology BV Medical SpecialtiesHealth Technology Develops products for minimally disruptive surgical treatments for the spine | Directeur Général | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 9 |
|---|---|
Progentix Orthobiology BV
Progentix Orthobiology BV Medical SpecialtiesHealth Technology Develops products for minimally disruptive surgical treatments for the spine | Health Technology |
IsoTis SA
IsoTis SA BiotechnologyHealth Technology Develops biomedical products | Health Technology |
University of London
University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Twente
University of Twente Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Leiden
University of Leiden Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Queen Mary University of London
Queen Mary University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kuros Biosciences Ltd.
Kuros Biosciences Ltd. BiotechnologyHealth Technology Develops biological products for tissue repair | Health Technology |
Xpand Biotechnology BV
Xpand Biotechnology BV BiotechnologyHealth Technology Develops innovative bioreactor technology for adherent cell expansion | Health Technology |
Scinus Cell Expansion BV
Scinus Cell Expansion BV BiotechnologyHealth Technology Develops and manufactures bioreactor solutions that simplify & streamline the production of advanced cell therapies | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national